Get Your Personalized Supplement StackSupplement Stack Quiz

A Proprietary Blend Of Clearphage

Q: Is Clearphage effective for treating bacterial infections?

Evidence for proprietary blends like Clearphage is limited; general phage therapy shows promise but clinical efficacy varies and requires further research.

Q: Is it safe to take orally?

Yes, oral phage therapy has demonstrated a good safety profile in clinical trials, with no significant adverse effects reported.

Q: How quickly does it work?

Antimicrobial effects can occur within hours in vitro; however, clinical effects may take longer and depend on the specific dosage and target.

Q: Can bacteria develop resistance?

Yes, bacteria can develop resistance to phages, which is a known challenge that may limit the long-term efficacy of phage therapy.

Q: Does it affect gut microbiota?

Phage therapy may alter gut microbiota composition due to its targeted action on bacteria, but without adverse effects reported in studies.

Also known as: A Proprietary Blend Of Clearphage, phage cocktails, phage therapy agents, Bacteriophage Blend

Overview

A Proprietary Blend Of Clearphage is a formulation based on bacteriophages, which are naturally occurring viruses that specifically infect and lyse bacteria. This blend is intended for antimicrobial purposes, potentially as a supplement to modulate gut microbiota or as an alternative/adjunct to antibiotics, especially against antibiotic-resistant bacteria. Key characteristics include their specificity to bacterial hosts, ability to destroy bacteria, and potential to alter microbiota composition. While phage therapy is a developing field with growing clinical interest, large-scale, high-quality randomized controlled trials (RCTs) for many proprietary blends like Clearphage are limited. General phage therapy shows promise, but direct independent peer-reviewed evidence for Clearphage specifically is not widely available.

Benefits

Phage therapy, in general, shows promise in reducing bacterial load, particularly in food safety applications against pathogens like *Listeria* and *Salmonella*, with significant antimicrobial effects demonstrated in meta-analyses. However, clinical trials in humans, such as those involving children with *E. coli* diarrhea, have shown oral phage administration to be safe but without significant improvement in diarrhea outcomes, possibly due to low phage titers or insufficient coverage. While potential modulation of gut microbiota without adverse effects has been observed, the clinical efficacy and specific benefits for human populations remain variable and often not statistically significant. The strength of evidence for proprietary blends like Clearphage is limited, and further human clinical trials are needed to confirm specific benefits and effect sizes.

How it works

Bacteriophages operate by specifically targeting and infecting bacteria. They attach to unique receptors on the bacterial surface, inject their genetic material, and then replicate inside the host cell. This replication process ultimately leads to the lysis (bursting) and destruction of the bacterial cell. When administered orally, phages primarily act locally within the gut lumen, infecting target bacteria without being significantly absorbed into the systemic circulation or harming human cells. Their mechanism is highly specific, relying on the recognition of bacterial surface proteins, which dictates their host range.

Side effects

Oral bacteriophage therapy, including proprietary blends, is generally considered safe with no significant adverse effects reported in clinical trials. Common side effects (occurring in >5% of users) have not been reported. Similarly, uncommon (1-5%) and rare (<1%) side effects, such as virulence gene transfer or pathogenicity from the phages used, have not been evidenced. There are no significant drug interactions reported. Contraindications are not well-defined, but caution is prudent in immunocompromised patients. While pediatric safety has been demonstrated in some studies, the efficacy in this population remains unclear. Overall, the safety profile appears favorable, but comprehensive long-term data for specific proprietary blends are still developing.

Dosage

The minimum effective dose for proprietary blends like Clearphage has not been definitively established. Clinical trials suggest that higher phage titers may be necessary for achieving significant efficacy in human applications. Optimal dosage ranges are dependent on the specific phage concentration within the blend and the target bacterial load. Food safety studies indicate dose-dependent effects. A maximum safe dose has not been defined, but oral administration appears safe at tested doses. Phage activity can be observed within hours, suggesting that repeated dosing may be required for sustained effects. The primary form is oral, targeting gut bacteria, and phages are known to survive gut transit but do not enter systemic circulation significantly.

FAQs

Is Clearphage effective for treating bacterial infections?

Evidence for proprietary blends like Clearphage is limited; general phage therapy shows promise but clinical efficacy varies and requires further research.

Is it safe to take orally?

Yes, oral phage therapy has demonstrated a good safety profile in clinical trials, with no significant adverse effects reported.

How quickly does it work?

Antimicrobial effects can occur within hours in vitro; however, clinical effects may take longer and depend on the specific dosage and target.

Can bacteria develop resistance?

Yes, bacteria can develop resistance to phages, which is a known challenge that may limit the long-term efficacy of phage therapy.

Does it affect gut microbiota?

Phage therapy may alter gut microbiota composition due to its targeted action on bacteria, but without adverse effects reported in studies.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC11845108/ – This systematic review and RCT investigated oral phage therapy in children with E. coli diarrhea. It found that while oral phages were safe, they did not significantly improve diarrhea outcomes, possibly due to low phage replication or insufficient coverage. The study highlights the safety but inconclusive efficacy in this specific pediatric population.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10612260/ – This systematic review and meta-analysis focused on patented phages for foodborne pathogens. It demonstrated significant antimicrobial effects of phages against Listeria and Salmonella in food matrices, identifying factors influencing their efficacy. The findings support the potential of phages in food safety applications, though not directly in human clinical settings.
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2025.1570665/full – This preclinical study characterized a novel phage, vB_SmaS_QH3, showing its ability to significantly inhibit bacterial growth in vitro and in an insect infection model. It also noted the emergence of bacterial resistance after 8-9 hours. This research provides insights into phage activity and the challenge of resistance, albeit in a non-human model.